Revance Reports Third Quarter 2023 Financial Results, Provid

– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy...

Related Keywords

Jordan , China , Markj Foley , Fosun Pharma , Guidepoint Qsight , Laurence Watts , Jessica Serra , Securities Exchange , Foley , Gilmartin Group , Allergan Inc , China National Medical Products Administration , Viatris Inc , Revance Therapeutics Inc , Exchange Commission , Linkedin , Revance Therapeutics , Athyrium Capital , Note Purchase Agreement , Chief Executive Officer Mark , Quarter Highlights , Erica Jordan , Senior Vice President , Chief Commercial Officer , National Medical Products Administration , Shanghai Fosun Pharmaceutical , Resilient Hyaluronic Acid , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Consolidated Statements , Months Ended September ,